Antipsychotic Treatment for Adolescents with Auditory and Visual Hallucinations

First-Line Treatment Selection

The American Academy of Child and Adolescent Psychiatry recommends atypical antipsychotics as the first-line choice for adolescents with psychotic symptoms, due to their equal efficacy to typical antipsychotics for positive symptoms and lower risk of extrapyramidal symptoms (EPS) 1, 2
Atypical antipsychotics, such as aripiprazole and risperidone, are FDA-approved for adolescent schizophrenia and have superior tolerability compared to typical antipsychotics 1

Aripiprazole is an excellent first choice, with lower EPS risk compared to risperidone, particularly at therapeutic doses 2
Risperidone is an alternative first-line option, with proven efficacy for controlling hallucinations and delusions, but requires cautious dosing due to increased EPS risk above 2 mg/day 3, 2
Quetiapine can be considered if sedation is needed, with a more sedating profile and lower EPS risk than risperidone 3, 2
Olanzapine is another reasonable option, with generally lower EPS risk and a recommended starting dose of 2.5 mg/day at bedtime 3, 2

Typical antipsychotics, such as haloperidol and fluphenazine, should not be used as first-line treatment in adolescents due to their high EPS risk and association with tardive dyskinesia 1, 3

The American Academy of Child and Adolescent Psychiatry recommends obtaining informed consent from the parent/guardian and assent from the adolescent, documenting specific target symptoms, and conducting baseline laboratory monitoring as required by the chosen agent 1
Regular monitoring for EPS is essential, rather than using prophylactic anticholinergics 2
An adequate therapeutic trial requires a sufficient dosage over 4-6 weeks minimum before determining treatment failure 1

The first strategy for managing EPS is to reduce the antipsychotic dose, followed by switching to an atypical antipsychotic with lower EPS risk if necessary 2
Prophylactic anticholinergics should not be used routinely, but may be reserved for significant EPS when dose reduction and switching have failed 4, 2

Clozapine should be reserved for treatment-resistant cases after failure of at least two other antipsychotic trials, and requires routine laboratory monitoring for agranulocytosis 1, 5

Antipsychotic treatment should be continued for at least 12 months after achieving remission, ideally 1-2 years for first-episode patients, due to the high relapse risk 1, 4
Monotherapy should be maintained whenever possible to minimize side effects and improve adherence 6, 7, 5

Antipsychotic medication must be combined with psychosocial interventions, such as cognitive-behavioral therapy (CBT) and psychoeducation, for optimal outcomes 1

The American Academy of Child and Adolescent Psychiatry recommends atypical antipsychotics, such as brexpiprazole, as first-line treatment for psychotic symptoms including hallucinations in patients with schizophrenia, due to equal efficacy for positive symptoms and lower extrapyramidal symptom risk compared to typical antipsychotics, with a strength of evidence level of high 8, 9

Brexpiprazole should be used as monotherapy whenever possible to minimize side effects and improve adherence in patients with schizophrenia, as antipsychotic polypharmacy is associated with increased side effect burden and medication complexity, with a moderate strength of evidence 8, 9